Navigation Links
Aton Pharma Launches Expanded Distribution and Marketing for Preservative-Free TIMOPTIC(R) in OCUDOSE(R)
Date:8/19/2009

LAWRENCEVILLE, N.J., Aug. 19 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

Aton will support TIMOPTIC in OCUDOSE with ophthalmic journal advertising, a couponing program, direct mail promotion and a patient information website (www.ocudose.com). Aton's sales force, which has been detailing LACRISERT since November 2008, will re-introduce TIMOPTIC in OCUDOSE to eye care professionals.

"As we have done with LACRISERT and other Aton products, we will concentrate on enhancing distribution, sampling and reimbursement assistance while increasing patient and provider awareness," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "With TIMOPTIC in OCUDOSE, we are able serve yet another niche market that is greatly underserved - glaucoma patients who will benefit from preservative-free medications."

"A preservative-free beta blocker is a consideration for many glaucoma patients, who must use medication frequently and for long periods of time," explained William Trattler, M.D., Director of Cornea at the Center of Excellence in Eyecare in Miami. "This is a particular concern for those who already have dry eye or are at increased
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... FL (PRWEB) June 19, 2013 At a ... the positive changes and growth that has occurred over the ... travel club. , Shuman said, "Travel Services has added vendors, ... heights beyond belief. Membership is up, even in the ... meet the demands of members." , Having been in the ...
(Date:6/19/2013)... In 2011, the value of the Serbian ... drugs form the largest sector, accounting for nearly one ... is a significant contributor to the local economy; it ... 50% of the total domestic chemical industry output fall ... and Zdravlje Actavis are key participants in the Serbian ...
(Date:6/19/2013)... the brink of extinction but can we finish the ... a Bristol academic addresses in his new book, published next ... University of Bristol, has produced the first comprehensive history of ... of polio explores the experiences of victims alongside the medical ... , According to a review by The Lancet ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Ultimate Medical ... Telethon, an 11.5-hour broadcast on WFLA News Channel 8. ... collected more than $84 million for All Children's Hospital ... event, themed "30 Years of Miracles," marked the second ... 18 UMA employees worked the phones during the Telethon, ...
(Date:6/19/2013)... Lexington, Mass. (PRWEB) June 19, 2013 ... IT security solutions, today announced that Imprivata OneSign ... KLAS® 2013 Mid-Term Performance Review: Software & Services ... by KLAS laud Imprivata on the superior performance of ... and support, and they indicate that Imprivata is integral ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Paralysed with fear: The story of polio 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
... , ALLEGAN, Mich., Nov. 9 Perrigo Company (Nasdaq: ... C. Papa will present at the Credit Suisse 18th ... 11:00 p.m. (MT) at the Arizona Biltmore Hotel in ... global healthcare supplier that develops, manufactures and distributes OTC ...
... Simple computerized alerts can help curb the impulse ... study in the August issue of Journal ... clinicians received computerized alerts, which compared medication brands, ... heavily marketed sleep medications to comparable generic equivalents. ...
... Research carried out among thousands of people has shown ... mass, leading to osteoporosis and fractures. This was ... head of the Brain and Behavior Laboratory, and Prof. Itai ... the relationship between depression and bone loss is particularly strong ...
... the clock 8 years, research shows , MONDAY, Nov. 9 ... improves so much that most feel eight years younger, a new ... everyone except a small minority -- only 2 percent -- who ... "The results really say three things: That work puts an extra ...
... announced today the acquisition of App Tech Global, Inc., which ... Natural Nutrition,s name will be changed to App Tech, Corp. ... of App Tech Global, Inc. , App Tech is developing ... App Tech is focused on multi platform apps designed ...
... China, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... leading pharmaceutical company,specializing in the development, manufacturing, and ... today announced an agreement,to acquire the manufacturing license ... Ltd. ("Tianda"). The acquisition of the,manufacturing license will ...
Cached Medicine News:Health News:Computerized support keeps prominence of name brand drugs at bay 2Health News:Connection between depression and osteoporosis detailed by Hebrew University researchers 2Health News:Retirement Brings Most a Big Health Boost 2Health News:Retirement Brings Most a Big Health Boost 3Health News:Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 2
(Date:6/19/2013)... -- A decade-long JDRF-funded study led by the Institute ... Germany , is providing a deeper understanding of ... type 1 diabetes (T1D), highlighting the importance of pre-diabetes ... "Seroconversion to Multiple Islet Autoantibodies and Risk of Progression ... The Journal of the American Medical Association . ...
(Date:6/19/2013)... 19, 2013  Finesse Solutions, Inc, a manufacturer ... process applications, announced the launch of its new ... culture and fermentation.  The 3L glass vessels are ... Finesse bioreactors and are designed to optimize yield ... fully compatible with all Finesse G3Lab controllers, and ...
(Date:6/19/2013)... 19, 2013  Decision Resources, one of the ... and healthcare issues, finds that, for the treatment ... and European rheumatologists cite a therapy,s induction of ... influences their prescribing decisions. Over 60 percent and ... rank the percentage of patients achieving remission at ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis 2
... 2011 Cell Therapeutics, Inc. ("CTI" or the "Company") ... results for the first quarter ended March 31, 2011. ... million through two financings, advanced pixantrone into a confirmatory ... Therapeutics Ltd. ("Chroma") to co-develop and market Chroma,s drug ...
... April 26, 2011 BD (Becton, Dickinson and Company) ... technology company, today reported quarterly revenues of $1.922 billion ... representing an increase of 6.8 percent from the prior-year ... percent, despite an unfavorable comparison to the prior year ...
Cached Medicine Technology:Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 2Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 3Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 4Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 5Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results 6BD Announces Results for 2011 Second Fiscal Quarter 2BD Announces Results for 2011 Second Fiscal Quarter 3BD Announces Results for 2011 Second Fiscal Quarter 4BD Announces Results for 2011 Second Fiscal Quarter 5BD Announces Results for 2011 Second Fiscal Quarter 6BD Announces Results for 2011 Second Fiscal Quarter 7BD Announces Results for 2011 Second Fiscal Quarter 8BD Announces Results for 2011 Second Fiscal Quarter 9BD Announces Results for 2011 Second Fiscal Quarter 10BD Announces Results for 2011 Second Fiscal Quarter 11BD Announces Results for 2011 Second Fiscal Quarter 12BD Announces Results for 2011 Second Fiscal Quarter 13BD Announces Results for 2011 Second Fiscal Quarter 14
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
10 L, Bulk Recommended for 5 and 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 L tip additionally combats contamination by keeping your pipettor out of 1.5 L and 2.0 L tubes....
1000 L, Bulk Recommended for 500 and 1000 L pipettes....
Medicine Products: